Resectable Pancreatic Cancer Clinical Trial
Official title:
A Pilot Phase II Multi Center Study of Gemcitabine and Nab-paclitaxel (Abraxane) as Preoperative Therapy for Potentially Operable Pancreatic Cancer
The main purpose of this research study is to evaluate whether Abraxane and gemcitabine are effective in treating patients with operable pancreatic cancer.
The best outcome for a patient diagnosed with pancreatic cancer is surgery. However many
patients have recurrence of the cancer after successful surgery. The investigators are
evaluating chemotherapy before surgery, which is a new approach.
In this study, Abraxane and gemcitabine will be tested as treatment for people with operable
pancreatic cancer to see if surgery can be successfully performed and if treatment will
reduce cancer cells in the tumor at surgery.
Abraxane is approved by the US FDA for the treatment of metastatic breast cancer after
failure of combination chemotherapy for metastatic disease or relapse within 6 months of
adjuvant chemotherapy. Gemcitabine is approved by the FDA for first line treatment for
patients with locally advanced or metastatic cancer of the pancreas.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05209074 -
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
| Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
| Recruiting |
NCT02243007 -
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05679050 -
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
| Withdrawn |
NCT01694589 -
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
|
Phase 0 | |
| Active, not recruiting |
NCT03138720 -
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT06363084 -
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
|
||
| Recruiting |
NCT04810910 -
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
|
Phase 1 | |
| Completed |
NCT01992705 -
Borderline Pancreas Study: FOLFIRINOX +SBRT
|
Early Phase 1 | |
| Completed |
NCT02047513 -
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
|
Phase 2 | |
| Completed |
NCT02115022 -
EUS vs. MDCT in Pancreatic Malignancy
|
||
| Recruiting |
NCT03492671 -
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
|
Phase 2 | |
| Terminated |
NCT05546411 -
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT06172036 -
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
|
Phase 2 | |
| Recruiting |
NCT05788744 -
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04737551 -
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
|
||
| Recruiting |
NCT03822936 -
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
|
Phase 2 | |
| Completed |
NCT03435536 -
Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer
|
N/A | |
| Terminated |
NCT05380557 -
ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic Testing
|